Finding ways to overcome resistance to radiation therapy in brain tumors.
Project 2: Overcoming GBM RT-resistance
This study is looking at how certain healthy cells around glioblastoma tumors might make the tumors tougher against radiation, and it aims to test a new treatment that combines a safe drug with regular radiation and chemotherapy to help improve outcomes for patients with this challenging brain cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10917028 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain tumor that often does not respond well to radiation therapy. The team aims to understand how non-cancerous cells in the tumor environment contribute to the tumor's resistance to radiation. By studying the metabolic processes involved, they plan to test a combination of an FDA-approved drug with standard radiation and chemotherapy in patients. This approach is designed to improve treatment outcomes for those affected by GBM.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard treatment involving radiation and chemotherapy.
Not a fit: Patients with other types of brain tumors or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment responses for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wahl, Daniel R — University of Michigan at Ann Arbor
- Study coordinator: Wahl, Daniel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.